EMA OKs Nucala for Severe Refractory Eosinophilic Asthma – Medscape


Medscape

EMA OKs Nucala for Severe Refractory Eosinophilic Asthma
Medscape
The European Medicines Agency (EMA) has approved mepolizumab (Nucala, GlaxoSmithKline) as an add-on treatment for severe refractory eosinophilic asthma in adults in the 31 European countries covered by the EMA, according to a company statement.
GSK gets European marketing rights for Nucala to treat asthmaThe Pharma Letter (registration)
EU OK for GSK's novel asthma biologicPharmaTimes
Nucala Now Available for Severe AsthmaMonthly Prescribing Reference (registration)
Drug Discovery & Development –StreetInsider.com –Zacks.com
all 22 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.